Trump Keeps His Promise, Dying Patients Get a Second Chance At Life

The Washington Examiner cited the Competitive Enterprise Institute on the direct toll to human life that regulations impose as a result of ever-increasing FDA clinical demands creating a bottle-neck process in the pharmaceutical market.    

Under the current model, even before the most promising drugs are permitted to enter the three-phase clinical trials, they must pass the FDA’s preclinical trial phase. This can take up to six years and requires the submission and approval of an Investigational New Drug application.
While drugmakers work their way through the FDA’s approval regime, people die and/or suffer in the interim. How many? Sam Kazman, general counsel at the Competitive Enterprise Institute, estimated in the Journal of American Physicians and Surgeons that hundreds of thousands of lives have been lost due to ever-increasing FDA clinical demands. Resources that pharmaceutical companies must use to move a drug through the bottleneck approval process are resources that cannot be used

Continue Reading....

Check Also

Trump Unveils His Pick to Head the White House’s Environmental Council

Facebook Twitter Google+ Pinterest LinkedIn Digg Del StumbleUpon E-mail Reddit Buffer Love ThisThe Daily Caller …

Leave a Reply

Send this to a friend